Heart transplant patients get hepatitis c cure hope
NCT ID NCT03886077
First seen May 21, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study looked at whether a 12-week course of glecaprevir/pibrentasivir can safely cure hepatitis C in heart transplant patients who got the virus from infected donors. Fifty adults on the transplant waitlist were enrolled, and those who received a hepatitis C-positive heart were treated after infection was confirmed. The main goal was to see if the virus stayed gone 12 weeks after treatment, with a secondary check on heart artery health one year later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glecaprevir/pibrentasivir
What this could lead to
If successful, this could show that treating hepatitis C after heart transplant is safe and effective, potentially improving outcomes for patients who receive infected donor hearts.
What could go wrong
This is a small, early study with only 50 participants and no blinding, so results may not apply to everyone. The long-term effects on heart health are still uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.